These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 10665838)

  • 1. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological interactions of statins.
    Paoletti R; Corsini A; Bellosta S
    Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
    Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
    BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
    Jorge PA; Almeida EA; Ozaki MR; Jorge M; Carneiro A
    Arq Bras Cardiol; 2005 Apr; 84(4):314-9. PubMed ID: 15880205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
    Mc Donnell CG; Shorten G; Van Pelt FN
    Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.